MedTrace Logo

Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus

NCT03260166 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-02-02

No results posted yet for this study

Summary

This clinical study will test the efficacy and safety of nicotinamide for lupus-associated skin lesions refractory to the treatment of hydroxychloroquine plus low-dose corticosteroids in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE).

Conditions

  • Cutaneous Lupus Erythematosus
  • Systemic Lupus Erythematosus Rash

Interventions

DRUG

nicotinamide

Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Hunan Provincial Natural Science Foundation of China

    collaborator UNKNOWN

  • National Key Clinical Specialty Construction Project of China

    collaborator UNKNOWN

  • Second Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Qianjin Lu, MD, PhD · Central South University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2020-01-01
Completion
2021-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03260166 on ClinicalTrials.gov